Bavarian Nordic Appoints Stenvall As President & CEO
(RTTNews) - Danish biopharmaceutical company Bavarian Nordic A/S (BAVA.CO) on Thursday announced the appointment of Tarja Stenvall as President and Chief Executive Officer, effective October 15, 2026.
Stenvall has more than 20 years of experience in the pharmaceutical industry, with roles spanning vaccines, commercial operations and business management. She will succeed Paul Chaplin, who is stepping down as CEO after 12 years in the role and 27 years with the company.
Stenvall most recently served as Senior Vice President and Head of the Global Franchise for Diabetes and Cardiovascular Diseases at Sanofi. Before joining Sanofi, she held commercial positions at AstraZeneca and Pfizer.
Bavarian's Chair of the Board, Anne Louise Eberhard, said Stenvall's experience across global pharmaceuticals and vaccines was a key factor in her appointment, as the company continues to focus on infectious diseases and public-health preparedness
Bavarian Nordic develops vaccines for infectious-disease and operates across Public Preparedness and Travel Health. Its portfolio includes vaccines against mpox, smallpox, chikungunya, tick-borne encephalitis and rabies. Its pipeline also includes vaccines targeting equine encephalitis, Lyme disease and Epstein-Barr virus (EBV).
Recent Financial & Stock Quote
Bavarian's Q2 2026 revenue rose 23% to DKK 2,034 million, compared to DKK 1,652 million in Q2 2025.
The company raised its full-year 2026 guidance, now expecting revenue of about DKK 5,700 million compared with full-year 2025 of DKK 6,244 million revenue.
Bavarian shares are trading up 1.89% at DKK 205.20.
